The Effect Lactate Administration on Cerebral Blood Flow During Hypoglycemia
Study Details
Study Description
Brief Summary
It is thought that altered brain lactate handling is involved in the development of impaired awareness of hypoglycemia (IAH), i.e. the inability to timely detect hypoglycemia in people with type 1 diabetes (T1DM). Infusion of lactate diminishes symptomatic and hormonal responses to hypoglycemia in patients with normal awareness of hypoglycemia (NAH), resembling the situation of patients with IAH. It is unknown whether this attenuating effect is due to brain lactate oxidation or the result of lactate-induced alterations of global and regional cerebral blood flow (CBF).
Normally, hypoglycemia causes a redistribution of CBF towards the thalamus, from where the sympathetic response to hypoglycemia is coordinated, but in IAH this effect is absent and global CBF is increased. We hypothesize that lactate infusion in patients with NAH will result in blunting of thalamic activation and/or enhanced global CBF. If so, these results may help delineating the pathogenesis of IAH which eventually creates new avenues to protect against the morbidity associated with hypoglycemia and IAH.
Study design: Single-blind placebo controlled, randomized cross-over intervention study Study population: T1DM patients with NAH (n=10) Intervention: On two separate occasions, patients with T1DM and NAH will undergo a hyperinsulinemic euglycemic-hypoglycemic glucose clamp with or without the infusion of exogenous lactate. ASL-MRI will be applied to measure global and regional changes in CBF.
Main study parameters/endpoints: The change in regional thalamic CBF in response to intravenous lactate infusion compared to placebo, during hypoglycemia
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Lactate infusion Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels |
Drug: Sodium Lactate
IV infusion
|
| Placebo Comparator: NaCl infusion As a control condition, subjects will receive intravenous NaCl infusion |
Drug: Sodium chloride
IV infusion
|
Outcome Measures
Primary Outcome Measures
- Regional CBF in ml/100g/min measured with ASL-MRI [during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)]
The change in regional thalamic CBF in response to intravenous lactate infusion compared to placebo, during hypoglycemia
Secondary Outcome Measures
- Global CBF in ml/100g/min measured with ASL-MRI [during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)]
The change in global CBF in response to intravenous lactate infusion
- Counterregulatory hormone responses to hypoglycemia [during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)]
The difference in adrenaline (pmol/L) responses to hypoglycemia during lactate infusion compared to placebo
- Symptom responses to hypoglycemia [during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)]
The difference in symptom responses to hypoglycemia (meausured with a validated questionnaire) during lactate infusion compared to placebo
- Measurements of metabolites in cell lysates or supernatants of the cultured immune cells [during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)]
The effect of lactate administration on immune cell function and metabolism
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diabetes duration ≥ 1 year
-
Age: 18-50 years
-
Body-Mass Index: 18-30 kg/m2
-
HbA1c: 42-75 mmol/mol (6-9%)
-
Outcome Clarke questionnaire: 0-1
-
Blood pressure: <160/90 mmHg
Exclusion Criteria:
-
Inability to provide informed consent
-
Use medication other than insulin, except for oral contraceptives or stable thyroxin supplementation therapy
-
Presence of any other medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or cardiac failure, known liver disease, anxiety disorders or a history of panic attacks.
-
Microvascular complications of T1DM: Proliferative retinopathy, symptomatic diabetic neuropathy (including autonomic neuropathy) or Nephropathy; clinical/overt albuminuria or an estimated glomerular filtration rate <60ml/min/1.73m2.
-
MRI contraindications (pregnancy, severe claustrophobia, metal parts in body)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Radoud university medical center | Nijmegen | Netherlands |
Sponsors and Collaborators
- Radboud University Medical Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Lactate_CBF